Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 42.00 | |
10 mg | In stock | $ 58.00 | |
25 mg | In stock | $ 105.00 | |
50 mg | In stock | $ 179.00 | |
100 mg | In stock | $ 325.00 | |
200 mg | In stock | $ 513.00 | |
500 mg | In stock | $ 818.00 |
Description | Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. |
Targets&IC50 | CXCR4:44 nM, CXCL12:5.7 nM |
In vitro | AMD 3100 can inhibit the replication of low-passage clinical HIV-1 isolates (K31, D370, K6/-2, HEM, and JRCSF) in primary T4 lymphocytes (EC50s: 0.16-1.5 ng/ml; EC90s: 0.36-4.7 ng/ml). In primary monocytes, AMD 3100 was active against HIV-1 (K31 and SF-162) at EC50s of 0.28-7.2 ng/mL and EC90s of 0.68-12 ng/mL. |
In vivo | Serum drug levels in rabbits given AMD 3100 (10 mg/kg) by the subcutaneous route were determined by a bioassay based on the EC50 of the compound required to inhibit HIV-1 cytopathicity in MT-4 cells. |
Cell Research | Plerixafor is dissolved in DMSO and then diluted with appropriate medium[2]. U87 mg cells are seeded in 96-well plates at the density of 6×103 cells in 200 μL/well and treated with CXCL12, Plerixafor or with peptide R, as described in the previous "Treatments" section. MTT (5 μg/mL) is added at each time point (24, 48, 72 h) during the final 2 h of treatment. After removing cell medium, 100 μL DMSO are added and optical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicates from three independent experiments[2]. |
Synonyms | JM3100 octahydrochloride, Plerixafor 8HCl (AMD3100 8HCl), Plerixafor 8HCl, SID791 octahydrochloride, AMD 3100 octahydrochloride, JM 3100 8HCl |
Molecular Weight | 794.46 |
Formula | C28H62Cl8N8 |
CAS No. | 155148-31-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Insoluble
H2O: 119.17 mg/mL (150 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Plerixafor octahydrochloride 155148-31-5 Autophagy GPCR/G Protein Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease CXCR Virus Protease AMD 3100 SID 791 SID-791 JM-3100 Octahydrochloride AMD-3100 Octahydrochloride SID-791 Octahydrochloride JM3100 Octahydrochloride AMD-3100 Plerixafor Octahydrochloride AMD3100 8HCl JM3100 octahydrochloride AMD3100 SID791 HIV CXC chemokine receptors SID 791 Octahydrochloride AMD3100 Octahydrochloride Plerixafor 8HCl (AMD3100 8HCl) AMD3100 octahydrochloride Human immunodeficiency virus inhibit JM 3100 Plerixafor 8HCl SID791 octahydrochloride Inhibitor JM-3100 AMD 3100 Octahydrochloride JM 3100 Octahydrochloride Plerixafor SID791 Octahydrochloride AMD 3100 octahydrochloride JM 3100 8HCl JM3100 inhibitor